NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of “Moderate Buy” by Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has earned an average rating of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.60.

Several equities analysts have commented on NPCE shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a report on Wednesday, August 14th. Wells Fargo & Company decreased their price objective on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th.

Insider Activity at NeuroPace

In related news, major shareholder Ltd. Kck sold 4,031 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74. Following the sale, the insider now owns 5,521,874 shares of the company’s stock, valued at $36,113,055.96. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 257,590 shares of company stock valued at $1,437,916. 22.20% of the stock is owned by insiders.

Hedge Funds Weigh In On NeuroPace

Several large investors have recently bought and sold shares of NPCE. Vanguard Group Inc. increased its stake in shares of NeuroPace by 18.3% in the first quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after buying an additional 75,512 shares during the period. Bank of New York Mellon Corp acquired a new position in NeuroPace in the 2nd quarter valued at approximately $257,000. Financial Advocates Investment Management increased its position in NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after acquiring an additional 5,000 shares during the period. Rhumbline Advisers bought a new position in shares of NeuroPace during the second quarter valued at $111,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of NeuroPace by 46.0% during the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock worth $520,000 after purchasing an additional 21,703 shares during the period. 78.83% of the stock is currently owned by institutional investors.

NeuroPace Trading Up 7.8 %

Shares of NeuroPace stock opened at $9.70 on Monday. NeuroPace has a 52-week low of $5.45 and a 52-week high of $18.15. The stock has a market cap of $289.53 million, a PE ratio of -9.70 and a beta of 1.79. The firm has a 50-day moving average of $7.13 and a 200-day moving average of $7.24. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The business had revenue of $21.06 million for the quarter, compared to the consensus estimate of $19.33 million. During the same quarter in the prior year, the business posted ($0.28) earnings per share. As a group, sell-side analysts forecast that NeuroPace will post -1 EPS for the current year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.